Cassava Sciences, Inc. Common Stock FLNA · Stock Open Cassava Sciences, Inc. Common Stock in new tab

1.03 USD

Add to portfolio

EPS

-0.87

P/B

0.56

ROE

-79.59

Beta

-0.74

Target Price

6.50 USD

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Cassava Sciences, Inc. Common Stock (FLNA)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Cassava Sciences, Inc. Common Stock Analysis (FLNA)

Official Website Stock

Is Cassava Sciences, Inc. Common Stock a good investment? Cassava Sciences, Inc. Common Stock (FLNA) is currently trading at 1.03 USD. Market analysts have a consensus price target of 6.50 USD. This suggests a potential upside from current levels.

Earnings Schedule: Cassava Sciences, Inc. Common Stock is expected to release its next earnings report on Aug. 5, 2026.

Investor FAQ

Does Cassava Sciences, Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Cassava Sciences, Inc. Common Stock?

Cassava Sciences, Inc. Common Stock is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of -0.87.

Company Profile

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Trades

Dividend History paid per year (USD)

Historical Dividends

Year	Total Dividends
▸2012	5.25 USD
Dec. 13, 2012	5.2500
▸2010	14.00 USD
Dec. 13, 2010	14.0000

Fundamentals

2026 © AllInvestView

Twitter YouTube Reddit Feature Requests Changelog Support Pricing Help

Support email: [email protected]

Terms of Service | Privacy Policy

Free Trackers · Dividend Apps · Tax Reporting · UK · Australia · Germany · Guides · Ticker Logos

Stock Directory · Financial Glossary · Portfolio Templates · Top Dividend Stocks · Investing in US · Investing in UK · Import Guides · Stock Comparison · Earnings Recaps

Data disclaimer: AIV (AllInvestView) assumes no liability for the information presented. Users are encouraged to exercise caution and carefully consider the accuracy, completeness, and relevance of the information provided.

It's important to remember that our website should complement your independent market research rather than replace it. The past performance of assets should not be regarded as a guarantee of future results. AllInvestView is not a registered investment advisor or broker/dealer, and the information presented here is for educational and informational purposes only. We value your trust and are committed to providing you with valuable market insights while emphasizing the importance of responsible decision-making in your investment journey.